Japan Prazosin Market Size, Share & Trends Analysis Report by Application (CVD, Neurological Disorder, Prostate Disorder, and Kidney Disorder), and Forecast 2020-2026.
Japan prazosin market is estimated to decline at a CAGR of around -2.6% during the forecast period. Prazosin hydrochloride (a derivative of Prazosin) is reported as an ingredient of Minipress in Japan and is used for the treatment of various diseases including BPH, heart failure, high blood pressure, and Raynaud's syndrome. According to the American Heart Association in 2018, 43 million people in Japan were hypertensive, of which only 50% are treated, and about 25% are controlled at the target blood pressure (BP) level of < 140/90 mm Hg. The large number of hypertensive populations coupled with its poor control rate; hypertension is one of the leading causes of mortality in the country. In addition, in July 2019, the two companies announced a definitive agreement for combining Mylan with Upjohn, Pfizer’s off-patent branded and generic established medicines business, creating a new global pharmaceutical company.
Japan prazosin market is segmented on the basis of application. Based on the application, the market is segmented into cardiovascular disease, neurological syndromes, prostate disorders, and kidney disorders. The CVD segment accounted for a significant share in the Japan prazosin market. CVDs claim to take more lives each year than all forms of cancer and chronic lower respiratory diseases altogether. Thus, prazosin is one of the treatments used for CVD mainly high BP and strokes. For instance, Minipress is specified for the treatment of hypertension, to control BP. Lowering blood pressure decreases the risk of fatal and nonfatal cardiovascular events, mainly strokes and myocardial infarction.
The companies which are contributing to the growth of the Japan prazosin market include Ajinomoto Co., Inc., Standard Chem and Pharmaceuticals Co. Ltd., Sun Pharmaceuticals Industries Ltd., Merck KGaA, Mylan N.V., Pfizer Inc., and others. The market players are considerably contributing to the market by the adoption of various strategies including new product launch, merger, and acquisition, collaborations to stay competitive in the market.
Research Methodology:
The market study of the Japan prazosin market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.
Secondary Sources Include:
The report is intended for prazosin market players, potential entrants, and pharmaceutical companies for the overall market and competitive analysis. The report provides an in-depth analysis on market size, products offered by the market players, and future market opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.
Market Segmentation:
1. Japan Prazosin Market Research and Analysis by Application
The Report Covers:
Japan prazosin market is estimated to decline at a CAGR of around -2.6% during the forecast period. Prazosin hydrochloride (a derivative of Prazosin) is reported as an ingredient of Minipress in Japan and is used for the treatment of various diseases including BPH, heart failure, high blood pressure, and Raynaud's syndrome. According to the American Heart Association in 2018, 43 million people in Japan were hypertensive, of which only 50% are treated, and about 25% are controlled at the target blood pressure (BP) level of < 140/90 mm Hg. The large number of hypertensive populations coupled with its poor control rate; hypertension is one of the leading causes of mortality in the country. In addition, in July 2019, the two companies announced a definitive agreement for combining Mylan with Upjohn, Pfizer’s off-patent branded and generic established medicines business, creating a new global pharmaceutical company.
Japan prazosin market is segmented on the basis of application. Based on the application, the market is segmented into cardiovascular disease, neurological syndromes, prostate disorders, and kidney disorders. The CVD segment accounted for a significant share in the Japan prazosin market. CVDs claim to take more lives each year than all forms of cancer and chronic lower respiratory diseases altogether. Thus, prazosin is one of the treatments used for CVD mainly high BP and strokes. For instance, Minipress is specified for the treatment of hypertension, to control BP. Lowering blood pressure decreases the risk of fatal and nonfatal cardiovascular events, mainly strokes and myocardial infarction.
The companies which are contributing to the growth of the Japan prazosin market include Ajinomoto Co., Inc., Standard Chem and Pharmaceuticals Co. Ltd., Sun Pharmaceuticals Industries Ltd., Merck KGaA, Mylan N.V., Pfizer Inc., and others. The market players are considerably contributing to the market by the adoption of various strategies including new product launch, merger, and acquisition, collaborations to stay competitive in the market.
Research Methodology:
The market study of the Japan prazosin market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.
Secondary Sources Include:
- Financial reports of companies involved in the market.
- Whitepapers, research-papers, and news blogs.
- Company websites and their product catalog.
The report is intended for prazosin market players, potential entrants, and pharmaceutical companies for the overall market and competitive analysis. The report provides an in-depth analysis on market size, products offered by the market players, and future market opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.
Market Segmentation:
1. Japan Prazosin Market Research and Analysis by Application
The Report Covers:
- Comprehensive research methodology of the Japan prazosin market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the Japan prazosin market.
- Insights about market determinants which are stimulating the Japan prazosin market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
Table of Contents
1. Report Summary
2. Market Overview and Insights
3. Competitive Landscape
4. Market Determinants
5. Market Segmentation
6. Company Profiles
Companies Mentioned
A selection of companies mentioned in this report includes:
- Ajinomoto Co., Inc.
- Johnlee Pharmaceuticals Pvt. Ltd.
- Merck KGaA
- Pfizer Inc.
- R&D Systems Inc.
- Renata Ltd.
- Mylan N.V.
- Standard Chem and Pharmaceuticals Co. Ltd.
- Sun Pharmaceuticals Industries Ltd.
- Teva Pharmaceuticals Industries Ltd.